Shanghai Fosun Pharmaceutical (Group) Co (HK:2196) has released an update.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has announced a proposed pre-conditional privatization of Henlius by merger, following an agreement on June 24, 2024. The merger will result in the absorption of Henlius by Fosun New Medicine, with shareholders receiving a cancellation price for their shares. Additionally, the company’s trading will resume, as detailed in the joint announcement.
For further insights into HK:2196 stock, check out TipRanks’ Stock Analysis page.
